Others (international travelers to countries with high orintermediate levels [HBsAg prevalence of ≥2%] [Box 3] of endemicHBV infection, persons with HCV infection, persons withchronic liver disease [including, but not limited to, thosewith cirrhosis, fatty liver disease, alcoholic liverdisease, autoimmune hepatitis, and an ALT or AST levelgreater than twice the upper limit of normal] [newrecommendation], persons with HIV infection, incarceratedpersons, all other persons seeking protection from HBVinfection without acknowledgement of a specific riskfactor). This evidence concerns the gene GPT and infection.